The total number of records retrieved from this search are 4. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3138	Virus nameHerpes simplex virus	Virus strainHSV-HSV-GR	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion of gamma 34.5 gene and insertion of GR and mcherry	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNational cell bak of Iran	Origin of cell lineMurine breast cancer cell line	Cell line4T1	Concentration of cell lineNA	In-vitro toxicityNA	AssayPhotomicrography and flow cytometry	In-vitro virus concentration1 MOI	In-vitro result27.9% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID30936930
IDOV_4282	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast carcinoma	Cell line4T1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result26.27 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5369	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine triple negative breast cancer cell line	Cell line4T1	Concentration of cell lineNA	In-vitro toxicityNA	AssayCoomassie brilinat blue staining	In-vitro virus concentration4 micromolar	In-vitro result70% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialIn clinical trial for various cancer cell line	PMID27503504
IDOV_5372	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 2 micromolar palcitaxel for 48 hours	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine triple negative breast cancer cell line	Cell line4T1	Concentration of cell lineNA	In-vitro toxicityNA	AssayCoomassie brilinat blue staining	In-vitro virus concentration4 micromolar	In-vitro result10% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectImpaired IFN beta production by combination	Clinical trialIn clinical trial for various cancer cell line	PMID27503504